Hyper Corporation

Hyper Corporation EBITDA per Employee

The EBITDA per Employee of Hyper Corporation (065650.KQ) as of Nov 5, 2026 is 41.65 M KRW. In the previous year, EBITDA per Employee was -21.07 M KRW — a change of -297.64% (higher).

EBITDA per Employee

41.65 MKRW

YoY

-297.64%

Last updated:

EBITDA per Employee of Hyper Corporation is 2025 41.65 M KRW. EBITDA per Employee of Hyper Corporation was 2024 -21.07 M KRW. It decreases by -297.64% higher compared to the previous year.

The Hyper Corporation EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2016
-57.68 M KRW
Jan 1, 2017
-182.66 M KRW
Jan 1, 2018
-92.78 M KRW
Jan 1, 2019
-33.60 M KRW
Jan 1, 2020
-29.79 M KRW
Jan 1, 2022
-194.09 M KRW
Jan 1, 2023
-21.07 M KRW
Jan 1, 2025
41.65 M KRW
The Hyper Corporation EBITDA per Employee history
YEAREBITDA per EmployeeYoY
41.65 MKRW-297.64%
-21.07 MKRW-89.14%
-194.09 MKRW+551.55%
-29.79 MKRW-11.33%
-33.60 MKRW-63.79%
-92.78 MKRW-49.20%
-182.66 MKRW+216.66%
-57.68 MKRW+204.58%
-18.94 MKRW-58.34%
-45.46 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyper Corporation Stock analysis

What does Hyper Corporation do? Hyper Corporation Inc generates revenue through the Information Technology Business segment, which manufactures and sells mouses, monitors, televisions, routers, and game devices, while also operating Internet portals and specialized sites. The New Drug Business segment develops and sells non narcotic analgesics, Alzheimer's treatments, and Alzheimer's dementia diagnosis kits. The company's IT products are purchased by consumers and businesses seeking technology solutions, while the pharmaceutical products target healthcare providers and patients requiring pain management and cognitive health support. The Information Technology Business segment benefits from the sale of hardware devices and digital content services, with Internet portals and specialized sites driving user engagement and advertising revenue. The New Drug Business segment focuses on medical solutions for chronic conditions, serving both institutional and individual markets through direct sales channels. Both segments operate under the same corporate structure, leveraging the company's existing infrastructure for product development and distribution. Hyper Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyper Corporation stock

EBITDA per Employee of Hyper Corporation is 41.65 M KRW in 2025.

EBITDA per Employee of Hyper Corporation changed from -21.07 M KRW to 41.65 M KRW, representing a -297.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Hyper Corporation since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Hyper Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Hyper Corporation

All Key Metrics — Hyper Corporation